WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 7, 431-445. Review Article ISSN 2277–7105

APPLICATION OF ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY AND PHARMACEUTICAL FORMULATION DEVELOPMENT

Yalisai Arasu S.*[1], Chandru B. S.[2], Nirmal Kumar R.[3], Anusha R.[4], Yogapriya G.[5]

[1]B. Pharm Student, G.P.Pharmacy College, Mandalavadi, Tirupattur, Tamil Nadu, India.

[2]Assistant Professor, Department of Pharmaceutics, G.P.Pharmacy College, Mandalavadi, Tirupattur, Tamil Nadu, India.

[3,4,5]B. Pharm Student, G.P. Pharmacy College, Mandalavadi, Tirupattur, Tamil Nadu, India.

Article Received on 28 Feb. 2026,
Article Revised on 19 March 2026,
Article Published on 01 April 2026,

https://doi.org/10.5281/zenodo.19327169

***Corresponding Author**

Yalisai Arasu S.

B. Pharm Student, G.P.Pharmacy College, Mandalavadi, Tirupattur, Tamil Nadu, India.

How to cite this Article: Yalisai Arasu S.*[1], Chandru B. S.[2], Nirmal Kumar R.[3], Anusha R.[4], Yogapriya G.[5] (2026). Application of Artificial Intelligence In Drug Discovery and Pharmaceutical Formulation Development. World Journal of Pharmaceutical Research, 15(7), 431–445.

ABSTRACT

AI is changing pharmaceutical research by allowing for data-driven decision-making in medication discovery and formulation development. Traditional pharmaceutical workflows are frequently constrained by long deadlines, large attrition rates, and substantial experimental trial-and-error, notably during target identification, lead optimization, and dosage-form design. These obstacles contribute to rising costs and delayed access to novel medicines Recent advances in machine learning (ML) and deep learning (DL) have resulted in computational algorithms that can analyze complicated biological, chemical, and formulation datasets with incredible speed and precision. In drug discovery, AI-based models aid in target selection, virtual screening, protein structure prediction, and early evaluation of pharmacokinetic and toxicity profiles, lowering the likelihood of late-stage failures.AI improves rational medication design by combining disparate information and shortens the time it takes to get from laboratory findings to clinical prospects. AI integration has had a substantial impact on formulation development. Predictive modeling can help with solubility estimation, excipient compatibility assessment, and formulation variable optimization, all of which are usually resource-intensive activities. When integrated with Quality by Design (QbD)

frameworks, AI allows for systematic examination of important quality features and process factors, resulting in robust and reproducible formulations. Furthermore, AI-driven techniques are increasingly being used to create innovative drug delivery systems (NDDS) such as nanoparticles, liposomes, microneedles, and smart polymers, which improves bioavailability and therapeutic results.

KEYWORDS: AI drug discovery, Machine learning, Deep learning, Target identification, Virtual screening, Solubility prediction, Excipient prediction.

1. INTRODUCTION

Drug discovery and pharmaceutical formulation development have always been challenging, resource-intensive, and time-consuming processes. Conventional medication delivery techniques sometimes face issues such as poor bioavailability, limited stability, and unanticipated patient responses. Along with significant attrition rates throughout clinical trials, it typically takes over 10 years and billions of dollars to go from the first compound identification to market approval. These disadvantages show how urgently innovative approaches that can reduce costs, speed up turnaround times, and boost the effectiveness of therapeutic interventions are needed. In recent years, advanced computational methods have grown more crucial to overcoming these challenges. By integrating comprehensive biological, chemical, and clinical data, computational modeling provides deeper insights into drug-target interactions, formulation design, and patient-specific reactions. However, because of the amount and complexity of biomedical data, more advanced technologies are required than can be supplied by traditional computer methods. As a result, artificial intelligence (AI) is now revolutionizing the pharmaceutical sciences. Algorithms for machine learning and deep learning can quickly evaluate large datasets, forecast molecular behavior, improve medication delivery systems, and create formulations with more accuracy. By customizing treatments to meet the needs of each patient, AI not only lessens the need for trial-and-error experimentation but also promotes customized therapy AI is therefore changing the example of drug discovery and formulation development by providing quicker, more affordable, and more dependable routes to market for innovative treatments.[1,2,3]

Figure 1: Artificial intelligence predictive modelling in nanomedicines, microfluidics, drug formulation, drug–excipient compatibility, drug solubility, bioavailability, and tailored medications.

2. BASICS OF ARTIFICIAL INTELLIGENCE IN PHARMA

2.1 ARTIFICIAL INTELLIGENCE AND PHARMACEUTICAL SCIENCES

Computational systems created to carry out operations that often call for human intellect, such as pattern recognition, learning from data, reasoning, and decision-making, are referred to as artificial intelligence (AI).[4] AI is being utilized more and more in pharmaceutical research to speed up drug development, enhance formulation procedures, and analyse sizable biological and chemical datasets.[5] In contemporary pharmaceutical research and development, traditional trial-and-error approaches are inefficient and resource-intensive, making artificial intelligence invaluable for managing complex, multidimensional datasets.[6]

2.2 MACHINE LEARNING [ML]

Machine learning (ML), a subfield of artificial intelligence, enables computers to learn from data without explicit programming.[7] Machine learning algorithms are taught on historical data to identify trends and predict future data. The three main categories of machine learning approaches are reinforcement learning, unsupervised learning, and supervised learning.[8] Supervised learning is frequently utilized in pharmaceutical research to simulate pharmacokinetic parameters, estimate solubility, and predict drug–target interactions.[9] Unsupervised learning facilitates the discovery of hidden patterns in biological information and the clustering of chemical molecules according to structural similarities.[10] In order to forecast stability results and optimize excipient selection, ML models are also used in formulation development.[11]

2.3 DEEP LEARNING (DL)

A sophisticated type of machine learning called deep learning (DL) models intricate correlations in big datasets by using multi-layered artificial neural networks.[12] Deep learning models are very useful for image analysis, genomic data interpretation, and molecular structure prediction because they can automatically extract characteristics from raw data, unlike typical machine learning techniques.[13] Deep learning has made a substantial contribution to drug design and protein structure prediction in pharmaceutical research. The ability of deep neural networks to precisely predict protein structures, which is essential for structure-based drug discovery, was shown by DeepMind systems.[14] DL techniques are also applied to virtual screening of huge chemical libraries and toxicity prediction.[15]

2.4 PREDICTIVE MODELING IN PHARMACEUTICAL R&D

Statistical and machine learning methods are used in predictive modelling to foresee results based on past data.[16] Predictive models are employed in pharmaceutical sciences to estimate the stability, bioavailability, dissolution rate, and solubility of drugs under different situations.[17] Quality by Design (QbD), in which formulation and process parameters are methodically tuned to guarantee constant product quality, heavily relies on predictive modelling. Researchers can decrease experimental trials and increase the effectiveness of decision-making in drug discovery and formulation development by incorporating machine learning algorithms into prediction frameworks.[18]

3. AI IN DRUG DISCOVERY

3.1 TARGET IDENTIFICATION

The first crucial stage of drug discovery is targets identification, which entails choosing biological entities that are essential to the development of a disease, such as proteins, enzymes, or receptors. Conventional techniques rely on costly and time-consuming biological testing and experimental screening. Rapid analysis of transcriptomic, proteomic, and genomic information to find possible therapeutic targets is made possible by artificial intelligence.[19] Large biological datasets can include hidden patterns found by machine learning algorithms, which can also more accurately predict genes linked to disease.[20] Target selection is made more reliable by using network-based AI models to investigate signalling cascades and protein–protein interactions.[21]

3.2 VIRTUAL SCREENING

To find possible therapeutic candidates that can bind to a biological target, virtual screening

entails the computational evaluation of sizable chemical libraries. Virtual screening powered by AI dramatically lowers the amounts of substances that need laboratory testing.[22] Target protein binding affinity is predicted by machine learning and deep learning models based on physicochemical and structural characteristics.[23] AI-based models increase the speed and accuracy of predictions when compared to traditional molecular docking.[24] Complex molecular representations like molecular graphs and SMILES strings are especially well-processed by deep neural networks.[25]

3.3 LEAD OPTIMIZATION

Once a promising chemical has been found, lead optimization seeks to minimize toxicity while enhancing potency, selectivity, and pharmacokinetic characteristics. Early on in the research process, AI models help forecast the features of absorption, distribution, metabolism, excretion, and toxicity (ADMET).[26] Machine learning techniques combined with Quantitative Structure–Activity Relationship (QSAR) models predict biological activity prior to synthesis, which aids in molecular structure optimization.[27] Additionally, generative models powered by AI can create new chemical compounds with enhanced medicinal qualities, speeding up the lead refining process.[28]

3.4 PROTEIN STRUCTURE PREDICTION

Structure-based medication design requires an understanding of a protein's three-dimensional structure. Accurate yet time-consuming experimental methods include cryo-electron microscopy and X-ray crystallography. Deep learning has changed the way that protein structure prediction works. Using sophisticated neural network architectures, DeepMind systems showed near-experimental accuracy in protein 3D structure prediction.[29] Reasonable drug design, drug binding research, and molecular docking are all improved by accurate protein models.[30]

3.4.1 MAJOR TOOLS USED IN PROTEIN STRUCTURE PREDICTION

- AI-Based Deep Learning Tools
  - ✓ AlphaFold
  - ✓ RoseTTAFold
- Homology Modeling Tools
  - ✓ SWISS-MODEL
  - ✓ MODELLER
- Hybrid / Threading Methods

- ✓ I-TASSER

4. AI IN PHARMACEUTICAL FORMULATION DEVELOPMENT

4.1 SOLUBILITY PREDICTION

A significant obstacle in medication development is poor water solubility, which has a direct impact on bioavailability. Extensive laboratory tests are necessary for traditional solubility testing. Predicting solubility based on molecular descriptors and physicochemical features is becoming more and more common with artificial intelligence models, especially machine learning methods.[31]

Early solubility and dissolution behaviour prediction is made possible by Quantitative Structure–Property Relationship (QSPR) models combined with machine learning approaches, which lessens the workload associated with experiments.[32] These forecasting tools let formulation scientists choose the best approaches, like solid dispersion, salt creation, or nanoparticle formulation.

4.2 EXCIPIENT PREDICTION

For pharmaceutical formulations to be stable and safe, drug–excipient compatibility is essential. Long-term stability testing in various environmental conditions is necessary for conventional compatibility investigations. To assess such incompatibilities, AI-based prediction systems examine interaction data and chemical structures.[33] The dependability of formulations can be increased by using machine learning algorithms to predict potential interactions between excipients and active pharmaceutical ingredients (APIs) and to identify degradation routes.[34]

4.3 OPTIMIZATION OF FORMULATION VARIABLES

Compression force, binder ratio, polymer concentration, and processing parameters are only a few of the variables that are involved in formulation creation. Conventional optimization techniques, such as factorial design or trial-and-error, might take a long time. By forecasting results like drug release profile, hardness, and stability, artificial intelligence (AI) methods like support vector machines (SVM) and artificial neural networks (ANN) are utilized to improve formulation parameters.[35] These models aid in increasing development efficiency and lowering the number of experimental batches needed.

4.4 AI IN QUALITY BY DESIGN (QbD)

Quality by Design (QbD) places a strong emphasis on risk management and methodical development with predetermined goals. Critical material attributes (CMAs) and critical process parameters (CPPs) can be predictively modelled. thanks to AI techniques, which improve QbD.[36] Scientific and risk-based approaches to pharmaceutical development are supported by regulatory frameworks like those offered by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. AI-powered models help define design space and enhance comprehension of the process.

Figure 2: Artificial Intelligence in Drug Development: Seven Transformative Applications".

Artificial intelligence is increasingly recognized as a transformative force in drug development, reshaping the entire pipeline from discovery to patient care. By integrating advanced algorithms into research, AI accelerates clinical trials through improved patient recruitment and real-time monitoring, while also enhancing the identification and validation of therapeutic targets. It enables the prediction of drug properties such as efficacy, toxicity, and pharmacokinetics, allowing researchers to prioritize promising compounds early in the process. AI contributes to dosage optimization by tailoring regimens to individual patient needs, supporting the broader movement toward precision medicine. In preclinical stages, computational models reduce reliance on animal testing by simulating biological responses, saving both time and resources. The technology also proven invaluable in processing vast genomic datasets, uncovering genetic variations that inform personalized treatment strategies. Finally, predictive analytics help anticipate potential side effects before large-scale trials, improving safety and reducing costly late-stage failures. Collectively, these applications

demonstrate how AI is not only streamlining drug development but also making it more efficient, precise, and patient-centered.

5. CHALLENGES AND LIMITATIONS OF ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY AND FORMULATION DEVELOPMENT

5.1 DATA DEPENDENCY

The standard, volume, and variety of training data have a significant impact on AI models. Datasets used in pharmacological research frequently suffer from

- Clinical data that is lacking or incomplete
- Tiny sample numbers
- Insufficient variety among patient groups
- Unreliable reporting guidelines

Inaccurate predictions in patient response prediction, pharmacokinetics modelling, and formulation optimization might result from low-quality datasets. Furthermore, data sharing is restricted by private industry databases, which lowers transparency and reproducibility. When models are trained on limited datasets, overfitting can occur, which can lead to decreased generalizability across populations.[37]

5.2 ALGORITHM BIAS

Algorithmic bias occurs when training datasets fail to sufficiently represent varied demographic or clinical characteristics. In medication delivery applications, biased models can;

- Misinterpret pharmacogenomic variations.
- Generate inaccurate dose predictions.
- Underperform in minority populations.

Bias can unintentionally exacerbate healthcare inequities. For example, AI-based predictive algorithms may outperform the dataset's represented populations while producing incorrect findings for underrepresented groups. Thus, dataset auditing, model validation across demographics, and continual performance monitoring are critical.[38]



Figure 3: Limitations and risks Used in Artificial intelligence.

5.3 REGULATORY VALIDATION

One of the most major challenges to AI integration in pharmaceutical sciences is regulatory acceptability. Drug development and delivery systems must adhere to stringent validation requirements specified by regulatory bodies, such as

- United States Food and Drug Administration
- European Medicine Agency
- The Central Drugs Standard Control Organization

AI models must demonstrate

- Transparency (explanation of algorithms)
- Reproducibility
- Robust validation
- Risk analysis and documentation

However, regulatory frameworks for adaptive and self-learning AI systems continue to evolve. The lack of standardized global rules causes ambiguity in approval pathways. Continuous-learning systems present additional issues since model outputs can vary over time, necessitating revalidation.[39]

5.4 ETHICAL CONCERNS

The following ethical concerns are brought up by the use of AI in medication distribution and

healthcare:

- Confidentiality and privacy of patient data
- Consent that is informed for AI-powered decision-making
- Responsibility in the event of inaccurate forecasts
- Risks associated with cybersecurity and data ownership

Data protection laws must be followed while using patient medical records to train AI models. Any compromise could result in private data being misused. Furthermore, in the event of unfavourable results, a lack of clarity on accountability among developers, physicians, and institutions leads to ethical and legal ambiguity. Therefore, ethical governance frameworks are necessary for the responsible and safe application of AI.[40]

6. FUTURE PERSPECTIVES

Future advancements in artificial intelligence in the pharmaceutical sciences will be expected to concentrate on system-level transformation as opposed to discrete applications.

6.1 AI-POWERED WHOLE-SYSTEM DRUG DEVELOPMENT PROCESS

Future platforms might integrate formulation design, manufacturing, lead optimization, and target identification into a continuous AI-assisted workflow. Early discovery data may directly feed formulation and scale-up plans if predictive models communicated across stages rather than operating as separate modules.[41]

6.2 DIGITAL TWIN TECHNOLOGY IN PHARMACEUTICAL MANUFACTURING

Digital twin systems, which are virtual duplicates of manufacturing processes that mimic powder flow, compression behaviour, dissolving performance, and stability under various environmental circumstances, may be the next breakthrough in AI for formulation development.

By combining artificial intelligence (AI) with sophisticated mathematical modelling tools, manufacturers might anticipate performance variations prior to physical production, increasing productivity and reducing batch failures.[42]

6.3 SELF OPTIMIZING CONTINUOUS MANUFACTURING

Artificial intelligence (AI)-driven feedback loops with real-time monitoring and parameter adjustment capabilities may be incorporated into future pharmaceutical production systems. These systems might automatically adjust for changes in material flow, pressure, or

temperature to keep product quality within predetermined bounds. The trend toward continuous manufacturing methods in the modern pharmaceutical industry is consistent with this strategy.

6.4 REASONABLE AND RELIABLE AI FRAMEWORK

Explainable AI (XAI) models will probably be given priority in future research as AI systems grow more complicated. Clinical adoption and regulatory approval will depend on transparent algorithms that offer interpretable decision routes. Another important area of development will be the creation of standardized validation frameworks for adaptive AI systems.[45]

Table 1: Comparison of AI Applications in Drug Discovery and Pharmaceutical Formulation Development.

Aspect	Drug Discovery	Pharmaceutical Formulation Development
Objective	Identify novel therapeutic molecules and validate biological targets	Design and optimize dosage forms for effective delivery and patient compliance
Data Sources	Genomic, proteomic, chemical libraries, biological assay data	Physicochemical properties, excipient compatibility, dissolution and stability data
AI Approaches	Deep learning, generative models, molecular docking, predictive analytics	Machine learning, neural networks, optimization algorithms, QSPR/QSAR modelling
Applications	- Target identification - Lead compound screening - Drug–target interaction prediction - De novo drug design	- Excipient selection - Stability prediction - Controlled-release design - Bioavailability enhancement
Impact on Timeline	Shortens discovery cycle from decades to a few years	Reduces trial-and-error in formulation, accelerating development
Cost Efficiency	Minimizes failed experiments and redundant screening	Cuts material wastage and lowers formulation costs
Challenges	- Data bias and quality issues - Need for experimental validation	- Limited datasets - Complexity of multi-component systems
Future Potential	AI-enabled precision medicine and personalized drug design	AI-guided individualized formulations and smart drug delivery

7. CONCLUSION

The pharmaceutical industry is changing as a result of artificial intelligence, which is making medication discovery and formulation development more efficient. Artificial Intelligence (AI) in drug discovery reduces the typically lengthy and expensive development cycle by

facilitating the quick identification of intriguing molecular targets, prediction of drug–target interactions, and effective lead optimization. AI helps formulation developers make data-driven choices for dosage form optimization, stability evaluation, and excipient selection, reducing experimental trial and error and speeding up product readiness. The integration of AI across several disciplines has great promise, despite the fact that there are still obstacles to overcome, including the necessity for experimental validation, regulatory acceptability, and the lack of sufficient datasets. AI opens the door for personalized medicine and intelligent drug delivery systems while also improving efficiency and cost effectiveness by fusing computational power with pharmacological knowledge. To sum up, the cooperation between regulatory bodies, pharmaceutical scientists, and computational specialists will be essential to maximizing AI's potential. The advancement of AI-driven drug discovery and formulations will move from experimental promise to commercial use as datasets get more comprehensive and validation mechanisms become more reliable. Going forward, the combination of AI with cutting-edge technologies like digital twins, nanotechnology, and real-world evidence platforms has the potential to completely transform intelligent drug delivery and tailored treatment. However, the extent to which AI transforms the pharmaceutical industry will ultimately depend on continued cooperation, moral supervision, and technological advancement.

8. REFERENCES

1. Sartaj A, Rajora A, Usmani J, Bana S, Annu, Ali J. AI-Driven Drug Formulation Development: Transforming the Future of Pharmaceutical Drug Development from Discovery to Regulatory Aspects. Journal of Pharmaceutical Innovation, Feb. 2026; 21(1): 54.
2. Bhupathyraaj M, Rani KR, Essa MM, editors. Artificial Intelligence in Pharmaceutical Sciences. CRC Press, 2023 Nov 23.
3. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, Zhao S. Applications of machine learning in drug discovery and development. Nature reviews Drug discovery, Jun. 2019; 18(6): 463-77.
4. Stuart J. Russell and Peter Norvig- Artificial Intelligence AModern Approach Third Edition., 2010.
5. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. Drug discovery and evaluation: safety and pharmacokinetic assays, Oct. 22, 2024; 1461-98.

6. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. Drug discovery and evaluation: safety and pharmacokinetic assays, Oct. 22, 2024; 1461-98.
7. Christopher M. Bishop- Pattern Recognition and Machine Learning Textbook, 2006.
8. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug discovery today, Jun. 1, 2018; 23(6): 1241-50.
9. Xu Y, Goodacre R. On splitting training and validation set: a comparative study of cross-validation, bootstrap and systematic sampling for estimating the generalization performance of supervised learning. Journal of analysis and testing, Jul. 2018; 2(3): 249-62.
10. Shah P, Kendall F, Khozin S, Goosen R, Hu J, Laramie J, Ringel M, Schork N. Artificial intelligence and machine learning in clinical development: a translational perspective. NPJ digital medicine, Jul. 26, 2019; 2(1): 69.
11. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature, May 28, 2015; 521(7553): 436-44.
12. umper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, Bridgland A. Highly accurate protein structure prediction with AlphaFold. Nature, Aug. 26, 2021; 596(7873): 583-9.
13. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, Zhao S. Applications of machine learning in drug discovery and development. Nature reviews Drug discovery, Jun. 2019; 18(6): 463-77.
14. Kuhn M, Johnson K. Applied predictive modeling. New York: Springer, 2013 Jan.
15. Moda TL, Montanari CA, Andricopulo AD. Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, Dec. 15, 2007; 15(24): 7738-45.
16. Konstantina K. Exarchos Themis P., Exarchos Konstantinos P., Karamouzis Michalis V., Fotiadis Dimitrios I. Machine learning applications in cancer prognosis and prediction. Computational and Structural Biotechnology Journal, 2015; 13: 8-17.
17. Schneider G. Automating drug discovery. Nature reviews drug discovery, Feb. 2018; 17(2): 97-113.
18. Zitnik M, Nguyen F, Wang B, Leskovec J, Goldenberg A, Hoffman MM. Machine learning for integrating data in biology and medicine: Principles, practice, and opportunities. Information Fusion, Oct. 1, 2019; 50: 71-91.
19. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nature reviews genetics, Jan. 2011; 12(1): 56-68.

20. Lavecchia A. Machine-learning approaches in drug discovery: methods and applications. Drug discovery today, Mar. 1, 2015; 20(3): 318-31.
21. Stepniewska-Dziubinska MM, Zielenkiewicz P, Siedlecki P. Development and evaluation of a deep learning model for protein–ligand binding affinity prediction. Bioinformatics, Nov. 1, 2018; 34(21): 3666-74.
22. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug discovery today, Jun. 1, 2018; 23(6): 1241-50.
23. Gawehn E, Hiss JA, Schneider G. Deep learning in drug discovery. Molecular informatics, Jan. 2016; 35(1): 3-14.
24. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, Zhao S. Applications of machine learning in drug discovery and development. Nature reviews Drug discovery, Jun. 2019; 18(6): 463-77.
25. Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M, Dearden J, Gramatica P, Martin YC, Todeschini R, Consonni V. QSAR modeling: where have you been? Where are you going to?. Journal of medicinal chemistry, Jun. 26, 2014; 57(12): 4977-5010.
26. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, Terentiev VA, Polykovskiy DA, Kuznetsov MD, Asadulaev A, Volkov Y. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature biotechnology, Sep. 2019; 37(9): 1038-40.
27. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, Bridgland A. Highly accurate protein structure prediction with AlphaFold. nature, Aug. 26, 2021; 596(7873): 583-9.
28. Senior AW, Evans R, Jumper J, Kirkpatrick J, Sifre L, Green T, Qin C, Žídek A, Nelson AW, Bridgland A, Penedones H. Improved protein structure prediction using potentials from deep learning. Nature, Jan. 30, 2020; 577(7792): 706-10.
29. Lusci A, Pollastri G, Baldi P. Deep architectures and deep learning in chemoinformatics: the prediction of aqueous solubility for drug-like molecules. Journal of chemical information and modeling, Jul. 22, 2013; 53(7): 1563-75.
30. Palmer DS, O'Boyle NM, Glen RC, Mitchell JB. Random forest models to predict aqueous solubility. Journal of chemical information and modeling, Jan. 22, 2007; 47(1): 150-8.
31. Waterman KC, Adami RC. Accelerated aging: prediction of chemical stability of pharmaceuticals. International journal of pharmaceutics, Apr. 11, 2005; 293(1-2): 101-25.

32. Skomski D, Ji A, Kuzman D, Clenet D, Hieb A, Roberts SW, Berry J, Lentes C, Weusten J, MacArthur K, Charles AS. Predictive stability in biopharmaceuticals and vaccines: Perspectives and recommendations towards accelerating patient access. Journal of pharmaceutical sciences, Aug. 1, 2025; 114(8): 103873.
33. Bourquin J, Schmidli H, van Hoogevest P, Leuenberger H. Application of artificial neural networks (ANN) in the development of solid dosage forms. Pharmaceutical development and technology, Jan. 1, 1997; 2(2): 111-21.
34. Holm P, Allesø M, Bryder MC, Holm R. Q8 (R2) Pharmaceutical Development. ICH quality guidelines: an implementation guide, Sep. 27, 2017; 535-77.
35. Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Computational and structural biotechnology journal, Jan. 1, 2015; 13: 8-17.
36. Max Kuhn · Kjell Johnson- Applied Predictive Modeling, 2013.
37. ICH Q8(R2)- Pharmaceutical Development.
38. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, Zhao S. Applications of machine learning in drug discovery and development. Nature reviews Drug discovery, Jun. 2019; 18(6): 463-77.
39. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, Zhao S. Applications of machine learning in drug discovery and development. Nature reviews Drug discovery, Jun. 2019; 18(6): 463-77.
40. Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. Artificial intelligence in drug discovery and development. *Drug discovery today*, 2021; *26*(1): 80–93. https://doi.org/10.1016/j.drudis.2020.10.010
41. Lee SL, O'Connor TF, Yang X, Cruz CN, Chatterjee S, Madurawe RD, Moore CM, Yu LX, Woodcock J. Modernizing pharmaceutical manufacturing: from batch to continuous production. Journal of Pharmaceutical Innovation, Sep. 2015; 10(3): 191-9.
42. Samek W, Wiegand T, Müller KR. Explainable artificial intelligence: Understanding, visualizing and interpreting deep learning models. arXiv preprint arXiv:1708.08296. 2017 Aug 28.